322 related articles for article (PubMed ID: 27650200)
21. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma.
Wu CW; Ng SC; Dong Y; Tian L; Ng SS; Leung WW; Law WT; Yau TO; Chan FK; Sung JJ; Yu J
Clin Cancer Res; 2014 Jun; 20(11):2994-3002. PubMed ID: 24691020
[TBL] [Abstract][Full Text] [Related]
22. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
Chen F; Dai X; Zhou CC; Li KX; Zhang YJ; Lou XY; Zhu YM; Sun YL; Peng BX; Cui W
Gut; 2022 Jul; 71(7):1315-1325. PubMed ID: 34462336
[TBL] [Abstract][Full Text] [Related]
24. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.
Zhu J; Djukovic D; Deng L; Gu H; Himmati F; Abu Zaid M; Chiorean EG; Raftery D
Anal Bioanal Chem; 2015 Oct; 407(26):7857-63. PubMed ID: 26342311
[TBL] [Abstract][Full Text] [Related]
25. [Metabolome Analysis of Human Serum: Implications for Early Detection of Colorectal Cancer].
Yamazaki Y
Rinsho Byori; 2015 Mar; 63(3):328-35. PubMed ID: 26524856
[TBL] [Abstract][Full Text] [Related]
26. Distinct urinary metabolic profile of human colorectal cancer.
Cheng Y; Xie G; Chen T; Qiu Y; Zou X; Zheng M; Tan B; Feng B; Dong T; He P; Zhao L; Zhao A; Xu LX; Zhang Y; Jia W
J Proteome Res; 2012 Feb; 11(2):1354-63. PubMed ID: 22148915
[TBL] [Abstract][Full Text] [Related]
27.
Lin Y; Ma C; Bezabeh T; Wang Z; Liang J; Huang Y; Zhao J; Liu X; Ye W; Tang W; Ouyang T; Wu R
Int J Cancer; 2019 Sep; 145(6):1679-1689. PubMed ID: 30720869
[TBL] [Abstract][Full Text] [Related]
28. Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.
Ni Y; Xie G; Jia W
J Proteome Res; 2014 Sep; 13(9):3857-70. PubMed ID: 25105552
[TBL] [Abstract][Full Text] [Related]
29. Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family.
Peltier J; Roperch JP; Audebert S; Borg JP; Camoin L
J Proteomics; 2016 Oct; 148():139-48. PubMed ID: 27492143
[TBL] [Abstract][Full Text] [Related]
30. Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling.
Djukovic D; Zhang J; Raftery D
Methods Mol Biol; 2018; 1765():229-240. PubMed ID: 29589312
[TBL] [Abstract][Full Text] [Related]
31. Multiple-matrix metabolomics analysis for the distinct detection of colorectal cancer and adenoma.
Zhang Y; Ni M; Tao Y; Shen M; Xu W; Fan M; Shan J; Cheng H
Metabolomics; 2024 Apr; 20(3):47. PubMed ID: 38642214
[TBL] [Abstract][Full Text] [Related]
32. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by
Gu J; Xiao Y; Shu D; Liang X; Hu X; Xie Y; Lin D; Li H
Dis Markers; 2019; 2019():3491852. PubMed ID: 31089393
[TBL] [Abstract][Full Text] [Related]
33. Serum metabolite signatures in normal individuals and patients with colorectal adenoma or colorectal cancer using UPLC-MS/MS method.
Guo J; Pan Y; Chen J; Jin P; Tang S; Wang H; Su H; Wang Q; Chen C; Xiong F; Liu K; Li Y; Su M; Tang T; He Y; Sheng J
J Proteomics; 2023 Jan; 270():104741. PubMed ID: 36174955
[TBL] [Abstract][Full Text] [Related]
34. Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites.
Gao R; Wu C; Zhu Y; Kong C; Zhu Y; Gao Y; Zhang X; Yang R; Zhong H; Xiong X; Chen C; Xu Q; Qin H
Gastroenterology; 2022 Oct; 163(4):1024-1037.e9. PubMed ID: 35788345
[TBL] [Abstract][Full Text] [Related]
35. Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics.
Wang Z; Cui B; Zhang F; Yang Y; Shen X; Li Z; Zhao W; Zhang Y; Deng K; Rong Z; Yang K; Yu X; Li K; Han P; Zhu ZJ
Anal Chem; 2019 Feb; 91(3):2401-2408. PubMed ID: 30580524
[TBL] [Abstract][Full Text] [Related]
36. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma.
Chang W; Wu L; Cao F; Liu Y; Ma L; Wang M; Zhao D; Li P; Zhang Q; Tan X; Yu Y; Lou Z; Zhao J; Zhang H; Fu C; Cao G
Clin Cancer Res; 2011 Sep; 17(17):5715-24. PubMed ID: 21771877
[TBL] [Abstract][Full Text] [Related]
37. Fecal Fatty Acid Profiling as a Potential New Screening Biomarker in Patients with Colorectal Cancer.
Song EM; Byeon JS; Lee SM; Yoo HJ; Kim SJ; Lee SH; Chang K; Hwang SW; Yang DH; Jeong JY
Dig Dis Sci; 2018 May; 63(5):1229-1236. PubMed ID: 29516324
[TBL] [Abstract][Full Text] [Related]
38. Metabonomics identifies serum metabolite markers of colorectal cancer.
Tan B; Qiu Y; Zou X; Chen T; Xie G; Cheng Y; Dong T; Zhao L; Feng B; Hu X; Xu LX; Zhao A; Zhang M; Cai G; Cai S; Zhou Z; Zheng M; Zhang Y; Jia W
J Proteome Res; 2013 Jun; 12(6):3000-9. PubMed ID: 23675754
[TBL] [Abstract][Full Text] [Related]
39. SWATHtoMRM: Development of High-Coverage Targeted Metabolomics Method Using SWATH Technology for Biomarker Discovery.
Zha H; Cai Y; Yin Y; Wang Z; Li K; Zhu ZJ
Anal Chem; 2018 Mar; 90(6):4062-4070. PubMed ID: 29485856
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
